New Butyroside D from Argan Press Cake Possess Anti-Melanogenesis Effect via MITF Downregulation in B16F10 and HEM Cells

Hyperpigmentation is a skin condition where patches of skin become darker in color due to excess melanin production upon UV exposure leading to melasma, which are lentigines or post inflammatory hyperpigmentation that psychologically affecting a great number of people. The present study investigates the anti-melanogenic effect of Butyroside D and the underling mechanism. After the confirmation of the non-cytotoxic effect of Butyroside D on B16F10 cells, we proceeded with analyzing the impact of the treatment at low and high concentration (i.e., 0.2 μM and 2 μM) using gene profiling analysis and examined the differentiation in gene expression. Our results identify cyclic adenosine monophosphate (cAMP), Wnt/β-catenin and Mitogen-Activated Protein Kinase (MAPK) signaling pathways to be downregulated upon treatment with Butyroside D. These pathways were targeted to further validate the effect of Butyroside D on membrane receptors melanocortin 1 receptor (MC1R) and receptor tyrosine kinase (c-Kit), related microphthalmia-associated transcription factor (MITF) and consequently tyrosinase (TYR), and tyrosine-related protein-1 (TYRP-1) that were all shown to be downregulated and, therefore, leading to the repression of melanin biosynthesis. Finally, the anti-melanogenic effect of Butyroside D was confirmed on human epidermal melanocytes (HEM) cells by inhibiting the activation of cAMP pathway generally mediated through α-melanocyte-stimulating hormone (α-MSH) and MC1R. Overall, this study suggests the potential applicability of this purified compound for the prevention of hyperpigmentation conditions.


Introduction
The process of melanin synthesis and distribution, also called melanogenesis, is initiated within the melanocytes, which are pigment producing dendritic cells [1]. Originally, melanocytes precursors, known as the melanoblasts, are unpigmented cells that originate from embryonic neural crest cells before migrating to the basal layer of skin epidermis and hair follicles [2][3][4]. The melanin is synthesized and stored in the melanocytes within lysosome-like organelles called the melanosomes before their transfer to the neighboring keratinocytes [5]. Specialized enzymes and structural proteins are, however, needed to produce melanin, including tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT) or TYRP2 [6]. These critical enzymes that affect the quantity and quality of melanin are under the influence of microphthalmia-associated transcription factors (MITF) that are . This data suggests the presence of a β-glucuronic acid unit, a β-Xyl unit, α-Rha unit, a β-Api unit, and an α-Ara unit. The analysis of obtained NMR spectral data were consistent with those published for Butyroside D [36]. Thus, the compound was identified as Butyroside D as represented in Figure 1.
to Butyroside D. Consequently, melanogenesis key related gene expression lev validated to further confirm the effect of Butyroside D on pigmentation upstream on B16F10 murine cells and on human epidermal melanocytes. To the bes knowledge, this study is the first describing the anti-melanogenesis effect of pur tyroside D. Hz, Ara H data suggests the presence of a β-glucuronic acid unit, a β-Xyl unit, α-Rha unit, unit, and an α-Ara unit. The analysis of obtained NMR spectral data were consist those published for Butyroside D [36]. Thus, the compound was identified as Bu D as represented in Figure 1.

Butyroside D Did Not Show a Cytotoxic Effect in B16F10
First, we evaluated the effect of Butryoside D in B16F10. Therefore, cells w tured and treated with various concentrations of the sample, then MTT assay w formed. Figure 2a confirms that at low concentrations, Butyroside D did not e toxicity to B16F10 cells. However, upon increasing the concentration of the treatm pure compound slightly altered the cells viability. Thus, further experimental d cused on the lowest concentration of 2 μM.

Butyroside D Did Not Show a Cytotoxic Effect in B16F10
First, we evaluated the effect of Butryoside D in B16F10. Therefore, cells were cultured and treated with various concentrations of the sample, then MTT assay was performed. Figure 2a confirms that at low concentrations, Butyroside D did not exert any toxicity to B16F10 cells. However, upon increasing the concentration of the treatment, the pure compound slightly altered the cells viability. Thus, further experimental design focused on the lowest concentration of 2 µM. Figure 2. Butryoside D has no cytotoxic effect in B16F10 and inhibit melanin production in B16F10 cells. (a) MTT assay was performed to assess the cell proliferation of Butryoside D-treated B16F10 cells varying concentration (2,4,6,8, and 10 μM). (b) The intracellular melanin content of B16F10 cells were assessed. B16F10 cells were treated with 2 μM Butryoside D or α-MSH as positive control, for 48 h. Results are presented as mean ± SD (n = 3). Statistical analysis was performed using oneway ANOVA where asterisks denote significant differences between the control and test groups being * p < 0.05 and ** p < 0.01.

Butyroside D Reduced the Melanin Content in B16F10
The melanin assay was conducted to determine the effect of Butyroside D on melanin production using B16F10 widely used in pigment cell studies as these cells can highly produce melanin without further stimulation from α-MSH [37]. Hence, cells were treated with only medium (negative control), 2 μM Butyroside D, or 0.1 μM α-MSH (positive control) for 48 h before conducting the assay. Figure 2b shows a significant reduction of melanin content in B16F10 cell upon treatment with 2 μM Butyroside D, as the melanin concentration value was recorded to 76% compared to the control. The -MSH positive control group showed an increase in melanin production up to 200%. Interestingly, this effect was observed without decreasing the cell viability for all treatments (Figure 2b). This result suggests that Butyroside D inhibited the melanogenesis in B16F10 cells.

Global Gene Profiling Analysis of Butyroside D in B16F10 Cells
A microarray analysis was performed to further investigate the molecular mechanism behind the effect of Butyroside D on B16F10 cells. Thus, the experiment was assessed using RNAs extracted from negative control, 0.2 μM, and 2 μM Butyroside D. An intensity value of total gene probe set after treatment with the samples compared to the untreated cells is displayed in volcano plots in Figure 3a,b. Probes with a threshold of fold change ≥ Results are presented as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA where asterisks denote significant differences between the control and test groups being * p < 0.05 and ** p < 0.01.

Butyroside D Reduced the Melanin Content in B16F10
The melanin assay was conducted to determine the effect of Butyroside D on melanin production using B16F10 widely used in pigment cell studies as these cells can highly produce melanin without further stimulation from α-MSH [37]. Hence, cells were treated with only medium (negative control), 2 µM Butyroside D, or 0.1 µM α-MSH (positive control) for 48 h before conducting the assay. Figure 2b shows a significant reduction of melanin content in B16F10 cell upon treatment with 2 µM Butyroside D, as the melanin concentration value was recorded to 76% compared to the control. The α-MSH positive control group showed an increase in melanin production up to 200%. Interestingly, this effect was observed without decreasing the cell viability for all treatments (Figure 2b). This result suggests that Butyroside D inhibited the melanogenesis in B16F10 cells.

Global Gene Profiling Analysis of Butyroside D in B16F10 Cells
A microarray analysis was performed to further investigate the molecular mechanism behind the effect of Butyroside D on B16F10 cells. Thus, the experiment was assessed using RNAs extracted from negative control, 0.2 µM, and 2 µM Butyroside D. An intensity value of total gene probe set after treatment with the samples compared to the untreated cells is displayed in volcano plots in Figure 3a,b. Probes with a threshold of fold change ≥ ±1.5 and p ≤ 0.05 were considered as differentially expressed genes (DEGs). Moreover, the volcano plots of the treatment against the control reveals the extent of FC and relative p-values after data normalization using the Expression Console Software (Figure 3a,b). The data revealed that in the case of 0.2 µM Butyroside D vs. the control, 3690 genes were differentially expressed, of which 2001 DEGs were up-regulated and 1689 DEGs down-regulated, whereas in the 2 µM Butyroside D vs. the control, 3690 genes were differentially expressed with 1693 up-regulated and 1926 down-regulated ( Figure 3c). In addition, the two treatment conditions were subjected to a comparison using hierarchical clustering, and the result showed similar tendencies in the affected genes between the two concentrations of the sample (Figure 3d).

Butyroside D Downregulated Melanogenesis-Associated Genes in B16F10 Cells
Next, the most regulated biological process (BPs) pathways were determined applying gene ontology (GO) and KEGG pathways analysis of DAVID and GSEA under the conditions qualifying a p-value ≤ 0.05 and containing more than two genes in each set. From the viewpoint of downregulated genes, GO analysis revealed an enrichment in cell differentiation, proliferation, morphogenesis, and cell cycle process from a low concentration treatment 0.2 μM Butyroside D ( Figure 4a). Furthermore, upon increasing the concentration of the treatment to 2 μM, additional GOs related to cell migration, melanocytes and pigment cell differentiation, cell cycle, regulation of cAMP metabolic process, Wnt signaling pathway, and aging were significantly inhibited ( Figure 4c). It is well known that the melanocytes are the pigment producing cells, in which the differentiation further stimulates their activity [38], whereas aging causes cells an unbalance and function distribution [39]. Thus, 2 μM Butyroside D reduced melanogenesis activity without altering melanocyte life cycle.

Butyroside D Downregulated Melanogenesis-Associated Genes in B16F10 Cells
Next, the most regulated biological process (BPs) pathways were determined applying gene ontology (GO) and KEGG pathways analysis of DAVID and GSEA under the conditions qualifying a p-value ≤ 0.05 and containing more than two genes in each set. From the viewpoint of downregulated genes, GO analysis revealed an enrichment in cell differentiation, proliferation, morphogenesis, and cell cycle process from a low concentration treatment 0.2 µM Butyroside D ( Figure 4a). Furthermore, upon increasing the concentration of the treatment to 2 µM, additional GOs related to cell migration, melanocytes and pigment cell differentiation, cell cycle, regulation of cAMP metabolic process, Wnt signaling pathway, and aging were significantly inhibited ( Figure 4c). It is well known that the melanocytes are the pigment producing cells, in which the differentiation further stimulates their activity [38], whereas aging causes cells an unbalance and function distribution [39]. Thus, 2 µM Butyroside D reduced melanogenesis activity without altering melanocyte life cycle.
The KEGG pathways analysis revealed that the low treatment concentration downregulated MAPK, cGMP-PKG, and PI3K-Akt signaling pathways. In addition, the higher concentration further downregulated the above mentioned pathways, along with reducing DEGs related to melanogenesis, melanoma, cAMP, and Rap1 signaling pathways (Figure 4b,d). These results revealed that Butyroside D have a depigmentation effect by inhibiting pathways involved in melanogenesis stimulation.
The KEGG pathways analysis revealed that the low treatment concentration downregulated MAPK, cGMP-PKG, and PI3K-Akt signaling pathways. In addition, the higher concentration further downregulated the above mentioned pathways, along with reducing DEGs related to melanogenesis, melanoma, cAMP, and Rap1 signaling pathways (Figure 4b,d). These results revealed that Butyroside D have a depigmentation effect by inhibiting pathways involved in melanogenesis stimulation.

Butyroside D Upregulated Oxidative Phosphorylation and Fatty Acid Elongation Associated GO and KEGG Pathways
Further analysis of the upregulated DEGs with Butyroside D was assessed. The GO analysis for both treatments was mostly focused on apoptotic process, oxidation reduction process, ATP, and the regulation of TOR signaling (Figure 4a,b). Studies have demonstrated the involvement of mTOR signaling in inducing hypopigmentation effects [40]. Consequently, this compound stimulated ATP content and, therefore, cell proliferation and melanogenesis inhibiting signaling.
The detailed upregulated genes enriched KEGG pathways in both conditions are related to fatty acid elongation, oxidative phosphorylation, and metabolic pathways (Figure

Butyroside D Upregulated Oxidative Phosphorylation and Fatty Acid Elongation Associated GO and KEGG Pathways
Further analysis of the upregulated DEGs with Butyroside D was assessed. The GO analysis for both treatments was mostly focused on apoptotic process, oxidation reduction process, ATP, and the regulation of TOR signaling (Figure 4a,b). Studies have demonstrated the involvement of mTOR signaling in inducing hypopigmentation effects [40]. Consequently, this compound stimulated ATP content and, therefore, cell proliferation and melanogenesis inhibiting signaling.
The detailed upregulated genes enriched KEGG pathways in both conditions are related to fatty acid elongation, oxidative phosphorylation, and metabolic pathways (Figure 4b,d). Putting this all together, Butyroside D may present a mitochondrial biogenesis stimulating effect while exhibiting an anti-melanogenesis activity.

Classification of DEGs Regulated by Butyroside D
In this section, we describe the top genes regulated by Butyroside D and the related pathways and functions involved. Two groups were formed for analysis, top upregulated DEGs, and top downregulated DEGs. Morpheus software version available online (https: //software.broadinstitute.org/morpheus/) was used for the schematic representation and heat map generation (Figure 5a). The top upregulated genes formed 6 subgroups, the genes were related to oxidative phosphorylation (Cox4i1, Ndufa10, Cox7c, Atp6v1d and Cox6c), fatty acid elongation (Hadhb, Acaa2, Acot1), oxidation reduction process (Sod2, Sod1), apoptotic signaling pathway (Acaa2, Dyrk2), TOR signaling (Tbc1d7, Gatsl2), and NADH dehydrogenase complex assembly (Ndufs8, Ndufaf6). On the other hand, the top downregulated genes formed 4 subgroups and were related to melanogenesis (Wnt5a, Mitf, Pomc, Mc1r, Kit), melanoma (Fgf9, Fgf12, Fgf2), MAPK signaling pathway (Ncam1, Prkcb, Map3k4, Pla2g4a, Mapk14, Mapk11), and aging (Tgfbr1, Il6, Nox4). The analysis shows a clear distinction between the lowest concentration treatment of 0.2 µM Butyroside D and further differentiation of gene expression when increasing the treatment concentration to 2 µM using the same pure compound. Collectively, Butyroside D decreased melanogenesisrelated genes and pathways, melanoma effectors, and aging mediators. On the other hand, it can be involved in stimulating ATP content and mitochondrial biogenesis. Results are presented as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA where asterisks denote significant differences between the control and test groups being * p < 0.05 and ** p < 0.01.

Validation Assay of the Effect of Butyroside D on Melanogenesis Downregulation in B16F10 Cells
In order to confirm and validate the causal effect of Butyroside D on melanogenesis downregulation, we quantified the gene expression of pigmentation related enzymes Tyr and Tyrp1 [41], and the related transcription factor Mitf [42] upon 24 h or 48 h treatment exposure using RT-PCR. Figure 5b shows a significant decrease in mRNA levels of Mitf and Tyrp1 in a time dependent manner when B16F10 cells are exposed to either 0.2 μM or 2 μM Butyroside D compared to the control. The same reducing effect was observed in the case of Tyr gene expression; however, no significant difference between the two used concentrations was perceived (Figure 5b). Additionally, 2 μM Butyroside D was capable Results are presented as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA where asterisks denote significant differences between the control and test groups being * p < 0.05 and ** p < 0.01.

Validation Assay of the Effect of Butyroside D on Melanogenesis Downregulation in B16F10 Cells
In order to confirm and validate the causal effect of Butyroside D on melanogenesis downregulation, we quantified the gene expression of pigmentation related enzymes Tyr and Tyrp1 [41], and the related transcription factor Mitf [42] upon 24 h or 48 h treatment exposure using RT-PCR. Figure 5b shows a significant decrease in mRNA levels of Mitf and Tyrp1 in a time dependent manner when B16F10 cells are exposed to either 0.2 µM or 2 µM Butyroside D compared to the control. The same reducing effect was observed in the case of Tyr gene expression; however, no significant difference between the two used concentrations was perceived (Figure 5b). Additionally, 2 µM Butyroside D was capable of the reduction of mRNA expression levels to significance of the two transcription factors Mc1r and Kit, highly involved in melanogenesis and melanocytes regulation [14], when compared to the control group after 6 h and 12 h of treatment (Figure 5c). This is consistent with microarray data shown in the Section 2.7 where the higher concentration of treatment exhibited a stronger activity on reducing melanogenesis related genes expression.

Effect of Butyroside D on Melanogenesis Downregulation in α-MSH Induced HEM Cells
First, various concentrations of Butyroside D were applied to HEM cells for 48 h to check for cytotoxicity, if any. Data showed that the concentrations applied did not exhibit a toxic effect; however, the viability slightly decreased starting at 4 µM, thus for the following experiment, 0.2 and 2 µM Butyroside D were used (Figure 6a). It is worth mentioning that melanogenesis is initiated by the binding of α-MSH to MC1R in melanocytes [43]; thus, to investigate depigmentation-related effect, the cells should be pigmented in advance. For this purpose, we extended our study to determine the effect of Butyroside D application in HEM cells treated with α-MSH. Figure 6 shows a significant decrease in mRNA expression of MITF, TYR, and TYRP1 after 48 h treatment compared to α-MSH-treated group. Additionally, higher concentration of 2 µM Butyroside D significantly reduced the expression of TYR and TYRP1 compared to the α-MSH treated group after 24 h, whereas no significant effect was noted when using low concentration of 0.2 µM Butyroside D. MITF gene expression was not reduced after 24 h treatment with both studied treatment concentrations. Overall, Butyroside D showed a similar tendency on HEM cells in reducing the expression of the melanogenic enzymes, and their transcription factor, strengthening our previous finding on B16F10 cells. of the reduction of mRNA expression levels to significance of the two transcription factors Mc1r and Kit, highly involved in melanogenesis and melanocytes regulation [14], when compared to the control group after 6 h and 12 h of treatment (Figure 5c). This is consistent with microarray data shown in the Section 2.7 where the higher concentration of treatment exhibited a stronger activity on reducing melanogenesis related genes expression.

Effect of Butyroside D on Melanogenesis Downregulation in α-MSH Induced HEM Cells
First, various concentrations of Butyroside D were applied to HEM cells for 48 h to check for cytotoxicity, if any. Data showed that the concentrations applied did not exhibit a toxic effect; however, the viability slightly decreased starting at 4 μM, thus for the following experiment, 0.2 and 2 μM Butyroside D were used (Figure 6a). It is worth mentioning that melanogenesis is initiated by the binding of α-MSH to MC1R in melanocytes [43]; thus, to investigate depigmentation-related effect, the cells should be pigmented in advance. For this purpose, we extended our study to determine the effect of Butyroside D application in HEM cells treated with α-MSH. Figure 6 shows a significant decrease in mRNA expression of MITF, TYR, and TYRP1 after 48 h treatment compared to α-MSHtreated group. Additionally, higher concentration of 2 μM Butyroside D significantly reduced the expression of TYR and TYRP1 compared to the α-MSH treated group after 24 h, whereas no significant effect was noted when using low concentration of 0.2 μM Butyroside D. MITF gene expression was not reduced after 24 h treatment with both studied treatment concentrations. Overall, Butyroside D showed a similar tendency on HEM cells in reducing the expression of the melanogenic enzymes, and their transcription factor, strengthening our previous finding on B16F10 cells. Statistical analysis was performed using one-way ANOVA where asterisks denote significant differences between α-MSH group and control or test groups being * p < 0.05 and ** p < 0.01.

Discussion
In the skin, melanocytes are found on the basal layer forming the epidermal melanin unit. The melanin is produced within the melanosomes of the melanocytes involving a series of signaling pathways [44]. In general, a mixed type of pheomelanin and eumelanin where melanin production was initially induced by α-MSH. Results are presented as mean ± SD (n = 3). Statistical analysis was performed using one-way ANOVA where asterisks denote significant differences between α-MSH group and control or test groups being * p < 0.05 and ** p < 0.01.

Discussion
In the skin, melanocytes are found on the basal layer forming the epidermal melanin unit. The melanin is produced within the melanosomes of the melanocytes involving a series of signaling pathways [44]. In general, a mixed type of pheomelanin and eumelanin polymer is synthesized, leading to the variation in skin and hair color. The alteration of melanin production may cause considerable problems of esthetic nature, and it can vary from hyperpigmentation to depigmenting conditions; therefore, it may have a high impact on patients' quality of life [45]. Hyperpigmentation is a skin condition where patches of skin become darker in color due to excess melanin production affecting all skin types [46]. Thus, it is important to explore treatment possibilities based on the prognosis to reduce the significant psychological impact and improve population healthy life, yet current therapies are still unfulfilled for skin pigmentation conditions [47]. Recently, there is a great demand for the development of safe and effective skin whitening agents [48], and several natural extracts have been proposed and identified to detain an inhibitory effect to melanin production [16][17][18]. In this current study, the effect of Butyroside D isolated from Argan press cake extract, previously reported to have a depigmentation activity, was extensively investigated in B16F10 cells and in human melanocytes (HEM) [29].
In melanogenesis studies, B16F10 cultured cells are widely used as a model for screening the anti-melanogenic effect of novel compounds [49]. After the confirmation of Butyroside D melanin reduction activity without affecting the cell viability on B16F10 cells, we proceeded with analyzing the impact of the treatment at low and high concentration (i.e., 0.2 µM and 2 µM) using DNA microarray technology. The biosynthesis of melanin is a result of a series of transformations and reactions engaging L-tyrosine mediated by the melanogenic enzymes under the influence of the transcription factor MITF, which is regulated by several signaling systems and transcription factors [50,51]. Thus, we investigated the effect of our sample on the up-stream related pathways controlling MITF. Our data showed a downregulation in the DEGs related to melanogenesis, cAMP, Wnt, and MAPK signaling pathways upon treatment with 2 µM Butyroside D. Furthermore, the pro-opiomelanocortin (Pomc) expression level was downregulated with the studied treatment of Butyrosiode D. The hormonal regulation of pigmentation is initiated with POMC proteolysis leading to melanotropins synthesis, namely α-, β-, and γ-MSH and ACTH. These melanotropins regulate pigmentation of many vertebrate species. The POMC level in skin is variable and is associated with physiological changes, UVR exposure, immune cytokine releases, and other cutaneous pathologies [52,53]. The role of cAMP pathway in melanin production and melanocyte survival is well-documented. Briefly, when α-MSH binds to the melanocytes master regulator MC1R, it induces cAMP activation, which in turn activates PKA to phosphorylate cAMP response element-binding protein (CREB) [54,55]. Consequently, CREB activates MITF, thus leading to the transcription of the melanogenesisrelated enzymes TYR, TYRP1, and DCT [56]. Mitogen-activated protein kinase (MAPK) family proteins, such as p38, are well known for their important role in melanogenesis regulation; the phosphorylation of p38-MAPK increases the expression of MITF and TYR, resulting in the stimulation of pigmentation [57][58][59]. Another critical pathway regulating the melanogenesis and was negatively affected by Butyroside D treatment is the Wnt/βcatenin pathway. In fact, this pathway enhances MITF expression at the transcriptional level and controls the melanocytes from embryonic to maturation stages throughout their development, survival, and differentiation [59]. Finally, Butyroside D also upregulated pathways involved in stimulating ATP content and mitochondrial biogenesis, in particular oxidative phosphorylation involved in cell metabolism and energy yielding [60,61].
Accumulating evidence showed the strong interaction between canonical Wnt pathway and KIT signaling in regulating pigmentation [62]. KIT is pivotal in the signaling pathway controlling the stimulation of pigmentation, and mutations or deletion may cause melanin distribution in mammals skin and hair [63]. In addition, KIT plays an important role in the melanogenesis pathway. It was reported that this factor acts on melanocytes stem cells regulation, proliferation, and apoptosis [64]. Therefore, targeting these mentioned pathways can present a useful tool for depigmentation studies, which was the case upon Butyroside D applications. Even though microarray analysis results present interesting findings related to the overall Butyroside D anti-melanogenesis effect, the B16F10 model presents some limitations, bearing in mind the nature of murine melanoma cells that presents abnormal functions.
To further validate our microarray results, we assessed gene expression levels of two membrane receptors MC1R and c-Kit. Our results showed a significant downregulation in their expression when applying 2 µM Butyroside D after 6 h and 12 h treatment. Accordingly, we observed a decrease in the expression of Mitf and, therefore, the melanogenesis enzymes Tyr and Tyrp1 upon our treatment. We mentioned earlier in this paper, the importance of MC1R in triggering melanogenesis-related pathways; for this reason, this receptor is often established as one of the main dictators and a positive regulator of skin pigmentation [65,66]. The Butyroside D mechanism of action can be explained by inhibiting the binding between the receptor and the ligand leading to the repression of melanin biosynthesis-related pathway and, therefore, the depigmentation effect. However, at the skin level, differences between humans and other mammals do not reside on the chemical pathways of melanin production itself but rather the melanin transfer from the skin to the hair in case of mammals, which gives little color to the skin, in contrast to humans, where the melanin is transferred to keratinocytes and stays in the skin [66]. Therefore, human melanocytes make a unique model for further investigation.
Thus, to confirm whether Butyroside D acts specifically on the receptors, we co-treated human melanocytes with our sample and α-MSH, as the interaction between α-MSH-MC1R triggers the activation of the cAMP and, therefore, MITF and melanin production. We have found that the co-treatment significantly decreased the expression of MITF, TYR, and TYRP1 compared with only α-MSH. This finding can be supported by several studies where whitening compounds act on reducing α-MSH and MC1R binding and activation, which will eventually affect the transcription of MITF and TYR [67][68][69]. According to the current findings, it could be assumed that Butyroside D exerts an anti-melanogenesis effect on both pigment cells, B16F10 murine cells and human melanocytes. This compound specifically targets the inhibition of pigmentation-related pathways and the upstream effectors. Furthermore, the effect of Butyroside D may support the advancement and the development of an alternative class of therapeutics derived from a natural compound and its application in skin related research. Still, future research and molecular docking studies should be investigated to further explore the mechanism of action by which Butyroside D acts on melanogenesis. Ex vivo or co-culture systems, including melanocytes and keratinocytes, could be used to validate the Butyroside D effect in an environment that mimics the human skin. Finally, MC1R-targeted inhibition could substantially confirm the molecular interaction of this novel compound with melanocyte membrane receptor.

General Experimental Procedures
The nuclear magnetic resonance (NMR) spectra were obtained with a JNM-ECS400 spectrometer (JEOL Ltd., Tokyo, Japan). The HRESI-MS data was recorded with a quadrupole time-of flight mass spectrometer (Agilent QTOF-LC-MS, Agilent Technologies, Santa Clara, CA, USA). Organic solvents were purchased from Wako Pure Chemical Industries (Osaka, Japan). Silica gel (75-120 mesh) and RP-C18 silica (38-63 µm) were purchased from Wako Pure Chemical Industries (Osaka, Japan). Biotage selekt (Uppsala, Sweden) equipped with NP-silica gel or RP-C18 flash columns chromatography were used for further fractionation. Purification of the isolated compounds was achieved by MPLC Pure C-850 Flash prep ® (Buchi, Flawil, Switzerland) with UV and ELSD detection and recycling preparative HPLC using a LaboAce LC-5060 system (Japan Analytical Industry, Osaka, Japan) equipped with Inertsil ODS-3, 5 µm, 20 × 250 mm, obtained from GL Sciences Inc., Tokyo, Japan. The analytical TLC was performed on precoated silica gel 60 GF254 (20 × 20 cm × 0.2 mm thick) or precoated RP-C18 F254 plates (5 × 7.5 cm × 0.2 mm thick) on aluminum sheets, both purchased from Merck Co., Darmstadt, Germany. The plates were developed using the appropriate solvent systems, and the developed chromatograms were examined under UV light 254 nm and 366 nm. The spots were made visible by spraying with vanillin/H 2 SO 4 reagent before warming in an oven preheated to 110 • C for 5 min.

Butyroside D Extraction and Isolation Procedures
Ten grams of the 80% EtOH extract of Argan press cake was chromatographed on Biotage Selekt (Biotage, Uppsala, Sweden) (MPLC using DCM: MeOH (100:0→0:100) on a prepacked normal phase flash silica gel column Biotage ® Sfär HC Duo (Biotage, Uppsala, Sweden) 100 g with a flow rate of 120 mL/min to give 13 fractions (Fr. 1~13  30) and applied to Inertsil ODS-3 column (5 µm, 20 × 250 mm, GL Sciences Inc., Japan) connected to recycling preparative LaboAce LC-5060 system (Japan Analytical Industry Co., Ltd., Japan) using a flow rate of 10 mL/min and RI and DAD detectors. The system was run with an isocratic elution of 0.1% FA/H 2 O: Acetonitrile (70:30). After one time recycling and manual collection of the resulting fractions (10 mL each), the target compound (7.8 mg) was isolated in a pure form. It has been identified as Butyroside D by comparing its physicochemical and spectral data with those reported in the literature [34].

Melanin Quantification
The release of melanin from the cells was determined as previously described with slight modifications [23]. Briefly, B16F10 cells were seeded and incubated overnight at 37 • C in a 5% CO 2 atmosphere at a density of 5 × 10 4 in 100 mm petri dish. The RPMI 1640 medium was then replaced with a fresh one in case of the control or Butyroside D (2 µM) diluted in the medium in case of target treatment or α-MSH (0.1 µM) for the positive control. After 48 h, the cells were harvested with trypsinization, and the viable cells were quantified using an automated cell counter. The cells were then solubilized using 0.1% Triton X-100 and precipitated using 10% trichloroacetate. Finally, the melanin was dissolved in 1 mL of 8 N NaOH and incubated for 2 h at 80 • C. The amount of melanin was determined after measuring the absorbance at 410 nm using Varioskan™ LUX. The melanin content was expressed as melanin content/cell (% of control).

RNA Extraction
The B16F10 cells or HEM cells were seeded at a density of 5 × 10 4 or 1 × 10 5 , respectively, in a 6 well plate and incubated overnight. After the removal of the medium, the cells were treated with 0 µM, 0.2 µM or 2 µM of Butyroside D and α-MSH (0.1 µM) for 24 h and 48 h, in the case of B16F10 cells. However, HEM cells were treated with a combination of 0.1 µM α-MSH and 0.2 µM or 2 µM of Butyroside D to further confirm the effect of our target compound on melanin production in these cells. RNA extraction was performed using ISOGEN reagent (Nippon Gene, Tokyo, Japan) following the manufacturer's instructions. RNA quantity and quality were determined using the NanoDrop 2000 spectrophotometer (ThermoScientific, Tokyo, Japan).

DNA Microarray
A microarray analysis was performed using Affymetrix's GeneChip ® System (Affymetrix Inc., Santa Clara, CA, USA) using Mouse Clariom S Array following the manufacturer's instructions. Briefly, the total RNA samples were prepared from the control group, 0.2 µM and 2 µM Butyroside D treated B16F10 cells (100 ng total RNA per sample) as described above. Next, complementary RNA (cRNA) was synthesized using IVT PLUS Reagent Kit (Affymetrix Inc., Santa Clara, CA, USA). The prepared samples were fragmented, labeled, and prepared for hybridization using a GeneChipTM Hybridization, Wash, and Strain Kit. Each specific sample was injected into the GeneChip TM cartridge of Clariom S Array and incubated with a rotation of 60 rpm for 16 h at 45°C in the GeneChip ® hybridization oven 645. The arrays were washed and stained with GeneChip ® Fluidic station 450 and scanned with GeneChip ® Scanner 3000. After the normalization of raw image data using Expression Console Software (Affymetrix, Tokyo, Japan, URL: http://www.affymetrix.com), further gene expression analysis was performed using Transcriptome Analysis Console (TAC) software (Version 4, Thermofisher Inc., Tokyo, Japan). Differentially expressed genes (DEGs) were extracted based on the Fold change (FC) and p-values (FC > 1.5 and p-values < 0.05). All data supporting the findings of this study are included; we have deposited the microarray data into the Gene Expression Omnibus (GEO).

Statistical Analysis
All experiments were conducted in triplicate. The mean and standard deviation are reported in the current study. A one-way ANOVA was performed when the two groups were compared. A p-value of ≤ 0.05 was considered significant.